The impact of rapid on-site evaluation (ROSE) on the quality and diagnostic value of thyroid nodule fine-needle aspirations.

Muri, Raphaela; Trippel, Mafalda; Borner, Urs; Weidner, Sabine E; Trepp, Roman (2022). The impact of rapid on-site evaluation (ROSE) on the quality and diagnostic value of thyroid nodule fine-needle aspirations. Thyroid, 32(6), pp. 667-674. Mary Ann Liebert 10.1089/thy.2021.0551

[img] Text
thy.2021.0551.pdf - Accepted Version
Restricted to registered users only until 3 March 2023.
Available under License Publisher holds Copyright.

Download (849kB) | Request a copy

BACKGROUND

Ultrasound-guided fine-needle aspiration (FNA) is the preferred method to evaluate the dignity of thyroid nodules. Nevertheless, the often-reported high non-diagnostic rate burdens affected patients and the healthcare system. Rapid on-site evaluation (ROSE) constitutes an addition to the thyroid FNA procedure, with various studies showing its beneficial effect on the Bethesda I non-diagnostic rate. We aimed to assess whether ROSE may reduce the rate of Bethesda categories III and V. Additionally, we examined the influence of ROSE on specimen quality.

METHODS

We performed a retrospective cohort study, comparing Bethesda categorization and specimen quality in specimens subject to ROSE compared to those not subject to ROSE. We also evaluated aspects of specimen quality that differed according to the use of ROSE. We subcategorized Bethesda I into insufficient cellularity or artifacts, and Bethesda categories III and V into cellular without artifacts, sparsely cellular, or artifacts.

RESULTS

We evaluated 5030 thyroid FNAs. ROSE was performed in 1304 (25.9%) cases, and ROSE was not utilized for 3726 (74.1%) specimens. The rate of Bethesda I non-diagnostic and Bethesda III categories was reduced in specimens subject to ROSE (4.3%, 56/1304), compared to non-ROSE (39.9%, 1487/3726, p<.001). The rate of both benign Bethesda II and malignant Bethesda VI diagnoses was 91.6% (1194/1270) in ROSE specimens, compared to 56.6% (1999/3530) in non-ROSE (p<.001). This was reflected by a significant improvement in diagnostic accuracy with ROSE (AUCnon-ROSE=0.811, AUCROSE=0.895, p=.004). The overall rate of specimens flawed by sparse cellularity in Bethesda categories III and V was 0.1% (1/1304) in ROSE specimens compared to 1.2% (45/3726) in non-ROSE (p<.001). The overall artifact rate was 0.3% (4/1304) for ROSE specimens and 2.5% (92/3726) for non-ROSE (p<.001).

CONCLUSIONS

ROSE significantly increased diagnostic accuracy by improving FNA specimens quantitatively and qualitatively. We suggest considering ROSE as standard of care for thyroid FNAs.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Endocrinology, Diabetology and Clinical Nutrition
04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Clinic of Nuclear Medicine
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ear, Nose and Throat Disorders (ENT)
04 Faculty of Medicine > Service Sector > Institute of Pathology > Cytopathology

Graduate School:

Graduate School for Health Sciences (GHS)

UniBE Contributor:

Muri, Raphaela; Trippel, Mafalda Arasceli; Borner, Urs; Weidner, Sabine Edith and Trepp, Roman

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1050-7256

Publisher:

Mary Ann Liebert

Language:

English

Submitter:

Pubmed Import

Date Deposited:

07 Mar 2022 10:28

Last Modified:

16 Jun 2022 00:12

Publisher DOI:

10.1089/thy.2021.0551

PubMed ID:

35236111

BORIS DOI:

10.48350/166578

URI:

https://boris.unibe.ch/id/eprint/166578

Actions (login required)

Edit item Edit item
Provide Feedback